Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
|Articles|February 28, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-03-05-2014
- Volume 10
- Issue 3
MedImmune Announces Research Collaboration with UC SanFrancisco
Author(s)Pharmaceutical Technology Editors
MedImmune and AstraZeneca enter a three-year collaboration with the Clinical and Translational Science Institute at the UC San Francisco.
Advertisement
MedImmune
, the biologics research and development arm of AstraZeneca, has entered into a three-year collaboration with the Clinical and Translational Science Institute (CTSI) at the University of California, SanFrancisco (UCSF). The collaboration will focus on CTSI’s Catalyst Awards program, which solicits applications from University scientists who wish to move their translational research into product development.
This marks the first industrial partnership for CTSI’s Catalyst Awards program’s therapeutic track, which focuses specifically on discovery and development of patient treatment options. The collaboration will benefit both MedImmune’s biologics and AstraZeneca’s small molecule portfolios and will call for proposals in therapeutic areas of interest to MedImmune and AstraZeneca, including cardiovascular and metabolic disease, oncology, respiratory, inflammation and autoimmunity, neuroscience and infectious disease.
Financial terms around the collaboration were not disclosed.
Source:
MedImmune
Articles in this issue
over 12 years ago
Top 10 Outsourcing Trends in Biopharmaceutical Manufacturingover 12 years ago
Local Knowledge Drives Global Market Expansionover 12 years ago
Regulatory Initiatives Spur API Supply Chain Securityover 12 years ago
Croda Receives Two EXCiPACT Certificationsover 12 years ago
Reaching China's Clinical Trial Marketover 12 years ago
Inflammatory Diseases Explained in Artistic Designsover 12 years ago
Almac Adds New Blistering TechnologyAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement